PARP1 and neoplasm: Caster and colleagues reported that pretreatment with veliparib (a PARP inhibitor) significantly augmented the increase in major histocompatibility complex class I (MHC-I) and PD-L1 expression in CT26 and MC38 tumours treated with IR.